Ironwood Pharmaceuticals, Inc.
(NASDAQ : IRWD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. 0.42%45.880.0%$164.22m
VRXValeant Pharmaceuticals International, Inc. 1.20%27.0714.1%$159.28m
ICLRICON plc -3.01%266.392.8%$148.40m
CTLTCatalent, Inc. -1.63%108.192.0%$126.87m
HZNPHorizon Therapeutics Plc 0.77%91.105.4%$109.12m
BHCBausch Health Cos., Inc. 1.20%27.070.0%$108.49m
JAZZJazz Pharmaceuticals Plc 0.49%144.302.1%$96.92m
UTHRUnited Therapeutics Corp. 2.87%213.9613.9%$84.79m
ARGXargenx SE 1.10%291.500.0%$67.46m
PRGOPerrigo Co. Plc 0.30%39.746.9%$54.41m
CORTCorcept Therapeutics, Inc. -0.54%18.455.5%$30.45m
PCRXPacira Biosciences, Inc. 4.48%64.089.8%$29.20m
BRBRBellRing Brands, Inc. 1.85%25.930.0%$27.94m
SAGESAGE Therapeutics, Inc. 1.23%42.937.6%$21.27m
IRWDIronwood Pharmaceuticals, Inc. 3.17%11.729.5%$20.44m

Company Profile

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.